Texbraska, yes I contacted the UCSF group a couple of times and suggested they review RVX-208 because they were excited about JQ1.  Had they not identified and talked about JQ1 as a potential treatment I may have not even thought to contact them.  It would have been a tragedy if they focused on JQ1 while not even being aware of Apabetalone, a much more tested, clinically advanced, undersood and safer drug, so I just couldn't stand-by and hope they would discover us on their own.  I received a thank you from from Dr Shokat for pointing out Apabetalone and a confirmation that they would include it.